Medicare Advantage Insurers Face U.S. Senate Scrutiny Over AI Used to Deny Medical Care

Major U.S. health insurance companies that administer Medicare Advantage programs are facing an unprecedented bipartisan Senate investigation. Senators Richard Blumenthal and Josh Hawley — representing opposite ends of the political spectrum — have joined forces to demand answers about the use of artificial intelligence in approving or denying medical services, according to STAT News AI.

What Is Medicare Advantage and Why Does This Investigation Matter?

Medicare Advantage is a federal program that allows Americans aged 65 and older to obtain health insurance managed by private companies rather than through the traditional government-run Medicare program. Millions of Americans rely on these plans to cover everyday medical expenses, from specialist consultations to hospital stays.

This is precisely why investigations into how some of the industry's largest players — UnitedHealth, Humana, and CVS — are using automated systems to make patient care decisions have sparked deep concern among lawmakers and public health experts alike.

Algorithms at the Center of the Controversy

According to STAT News AI, the senators formally requested internal documents to clarify the extent to which artificial intelligence tools are involved in decisions to delay or deny patients' access to treatment. The core concern is that algorithms — originally designed to streamline administrative processes — may be systematically used to restrict medical care, with direct consequences for patients' health outcomes.

If confirmed by the documents, this practice could represent a major systemic problem: complex medical decisions that should involve a physician's clinical judgment would instead be delegated to computational models.

A Rare Political Consensus in the United States

The bipartisan coalition that has formed around this issue is notable in its own right. In an intensely polarized American political climate, a Democratic senator and a Republican senator have chosen to act together — a signal that concerns about the impact of artificial intelligence on patients' rights transcend ideological boundaries.

According to STAT News AI, the pressure being applied to the companies is aimed at obtaining "documents related to AI use." The responses that UnitedHealth, Humana, and CVS provide could shape the regulatory framework for artificial intelligence in healthcare for years to come.

A Precedent With Global Implications

The debate unfolding in the United States is being watched closely in Europe as well, including in Romania, where healthcare systems are increasingly exploring the use of AI technologies in managing medical records and decision-making processes. The case of the American insurers raises fundamental questions about transparency, accountability, and the limits of automation when the stakes are human health.